The DOI matches its Crossref record; 22 of the 22 references it cites were found in a registry or an index.
Generation of T-Cell Immunity to the HER-2/neu Protein After Active Immunization With HER-2/neu Peptide–Based Vaccines
Abstract
PURPOSE: The HER-2/neu protein is a nonmutated tumor antigen that is overexpressed in a variety of human malignancies, including breast and ovarian cancer. Many tumor antigens, such as MAGE and gp100, are self-proteins; therefore, effective vaccine strategies must circumvent tolerance. We hypothesized that immunizing patients with subdominant peptide epitopes derived from HER-2/neu, using an adjuvant known to recruit professional antigen-presenting cells, granulocyte-macrophage colony-stimulating factor, would result in the generation of T-cell immunity specific for the HER-2/neu protein. PATIENTS AND METHODS: Sixty-four patients with HER-2/neu–overexpressing breast, ovarian, or non–small-cell lung cancers were enrolled. Vaccines were composed of peptides derived from potential T-helper epitopes of the HER-2/neu protein admixed with granulocyte-macrophage colony-stimulating factor and administered intradermally. Peripheral-blood mononuclear cells were evaluated at baseline, before vaccination, and after vaccination for antigen-specific T-cell immunity. Immunologic response data are presented on the 38 subjects who completed six vaccinations. Toxicity data are presented on all 64 patients enrolled. RESULTS: Ninety-two percent of patients developed T-cell immunity to HER-2/neu peptides (stimulation index, 2.1 to 59) and 68% to a HER-2/neu protein domain (stimulation index range, 2 to 31). Epitope spreading was observed in 84% of patients and significantly correlated with the generation of a HER-2/neu protein–specific T-cell immunity (P = .03). At 1-year follow-up, immunity to the HER-2/neu protein persisted in 38% of patients. CONCLUSION: The majority of patients with HER-2/neu–overexpressing cancers can develop immunity to both HER-2/neu peptides and protein. In addition, the generation of protein-specific immunity, after peptide immunization, was associated with epitope spreading, reflecting the initiation of an endogenous immune response. Finally, immunity can persist after active immunizations have ended.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Studies of the HER-2/ neu Proto-Oncogene in Human Breast and Ovarian Cancer
Slamon, D. J., Godolphin, W., Jones, L. A., Holt, J. A., Wong, S. G., Keith, D. E., Levin, W. J., Stuart, S. G., Udove, J., Ullrich, A., et al. (1989) · Science · doi:10.1126/science.2470152 · Cited by 6,816
Coussens, L., Yang-Feng, T. L., Liao, Y.-C., Chen, E., Gray, A., McGrath, J., Seeburg, P. H., Libermann, T. A., Schlessinger, J., Francke, U., et al. (1985) · Science · doi:10.1126/science.2999974 · Cited by 1,814
Spreading of T-cell autoimmunity to cryptic determinants of an autoantigen
Lehmann, P. V., Forsthuber, T., Miller, A., & Sercarz, E. E. (1992) · Nature · doi:10.1038/358155a0 · Cited by 1,186
The neu oncogene encodes an epidermal growth factor receptor-related protein
Bargmann, C. I., Hung, M.-C., & Weinberg, R. A. (1986) · Nature · doi:10.1038/319226a0 · Cited by 1,117
Expression of the HER-2/neu proto-oncogene in normal human adult and fetal tissues.
Press, M. F., Cordon‐Cardo, C., & Slamon, D. J. (1990) · PubMed · Cited by 638
Existent T-cell and antibody immunity to HER-2/neu protein in patients with breast cancer.
Disis, M. L., Calenoff, E., McLaughlin, G., Murphy, A. E., Chen, W., Groner, B., Jeschke, M., Lydon, N., McGlynn, E., & Livingston, R. B. (1994) · PubMed · Cited by 524
Self-citationKnutson, K. L., Schiffman, K., & Disis, M. L. (2001) · Journal of Clinical Investigation · doi:10.1172/jci11752 · Cited by 439
Self-citationDisis, M. L., Grabstein, K. H., Sleath, P. R., & Cheever, M. A. (1999) · PubMed · Cited by 340
Self-citationVanderlugt, C. J., & Miller, S. D. (1996) · Current Opinion in Immunology · doi:10.1016/s0952-7915(96)80012-4 · Cited by 331
Disis, M., Bernhard, H., Shiota, F., Hand, S., Gralow, Jr., Huseby, E., Gillis, S., & Cheever, M. (1996) · Blood · doi:10.1182/blood.v88.1.202.202 · Cited by 329
Self-citationKaplan, G., Walsh, G., Guido, L. S., Meyn, P., Burkhardt, R. A., Abalos, R. M., Barker, J., Frindt, P. A., Fajardo, T. T., & Celona, R. (1992) · The Journal of experimental medicine · doi:10.1084/jem.175.6.1717 · Cited by 263
Lifelong protection against hepatitis B: the role of vaccine immunogenicity in immune memory
Banatvala, J., Van Damme, P., & Oehen, S. (2000) · Vaccine · doi:10.1016/s0264-410x(00)00224-3 · Cited by 213
Improving Vaccine Performance with Adjuvants
Vogel, F. R. (2000) · Clinical Infectious Diseases · doi:10.1086/313883 · Cited by 202
Induction of anti-self-immunity to cure cancer
Nanda, N. K., & Sercarz, E. E. (1995) · Cell · doi:10.1016/0092-8674(95)90047-0 · Cited by 196
Peptide-based, but not whole protein, vaccines elicit immunity to HER-2/neu, oncogenic self-protein
Disis, M. L., Gralow, J. R., Bernhard, H., Hand, S. L., Rubin, W. D., & Cheever, M. A. (1996) · The Journal of Immunology · doi:10.4049/jimmunol.156.9.3151 · Cited by 179
Self-citationHER-2/neu Protein: A Target for Antigen-Specific Immunotherapy of Human Cancer
(1997) · Advances in Cancer Research · doi:10.1016/s0065-230x(08)60103-7 · Cited by 166
Disis, M. L., Knutson, K. L., Schiffman, K., Rinn, K., & McNeel, D. G. (2000) · Breast Cancer Research and Treatment · doi:10.1023/a:1006438507898 · Cited by 159
Self-citationDrakesmith, H., O′Neil, D. A., Schneider, S. C., Binks, M., Medd, P. G., Sercarz, E. E., Beverley, P. C. L., & Chain, B. (1998) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.95.25.14903 · Cited by 118
Disis, M. L., Schiffman, K., Gooley, T. A., McNeel, D. G., Rinn, K. J., & Knutson, K. L. (2000) · PubMed · Cited by 112
Self-citationEl‐Shami, K., Tirosh, B., Bar‐Haim, E., Carmon, L., Vadai, E., Fridkin, M., Feldman, M., & Eisenbach, L. (1999) · European Journal of Immunology · doi:10.1002/(sici)1521-4141(199910)29:10<3295::aid-immu3295>3.0.co;2-n · Cited by 85
Driver Clones and Determinant Spreading
Sercarz, E. E. (2000) · Journal of Autoimmunity · doi:10.1006/jaut.2000.0380 · Cited by 81
Antigen Processing Differences Among APC
Schneider, S. C., & Sercarz, E. E. (1997) · Human Immunology · doi:10.1016/s0198-8859(97)00079-7 · Cited by 36
Cited by
Immunotherapy of Diffuse Gliomas: Biological Background, Current Status and Future Developments
Grauer, O. M., Wesseling, P., & Adema, G. J. (2009) · Brain Pathology · doi:10.1111/j.1750-3639.2009.00315.x · Cited by 4,007
Trastuzumab — Mechanism of Action and Use in Clinical Practice
Hudis, C. A. (2007) · New England Journal of Medicine · doi:10.1056/nejmra043186 · Cited by 2,585
Morgan, R. A., Yang, J. C., Kitano, M., Dudley, M. E., Laurencot, C. M., & Rosenberg, S. A. (2010) · Molecular Therapy · doi:10.1038/mt.2010.24 · Cited by 2,533
Mechanisms of Disease: understanding resistance to HER2-targeted therapy in human breast cancer
Nahta, R., Yu, D., Hung, M.-C., Hortobagyi, G. N., & Esteva, F. J. (2006) · Nature Clinical Practice Oncology · doi:10.1038/ncponc0509 · Cited by 916
Therapeutic vaccines for cancer: an overview of clinical trials
Melero, I., Gaudernack, G., Gerritsen, W., Huber, C., Parmiani, G., Scholl, S., Thatcher, N., Wagstaff, J., Zielinski, C., Faulkner, I., et al. (2014) · Nature Reviews Clinical Oncology · doi:10.1038/nrclinonc.2014.111 · Cited by 776
Metadata
- Authors
- Disis, M. L., Gooley, T. A., Rinn, K., Davis, D., Piepkorn, M., Cheever, M. A., Knutson, K. L., & Schiffman, K.
- Venue
- Journal of Clinical Oncology
- Published
- 2002-06-01
- Volume
- 20
- Issue
- 11
- Pages
- 2624-2632
- ISSN
- 0732-183X (ISSN-L)
- 1527-7755
- OpenAlex
- W2009648532
- Cited by
- 423
- References
- 22
- FWCI
- 11.17
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.